USANA Health Sciences (NYSE: USNA) reported Q3 EPS of $1.36, $0.06 better than the analyst estimate of $1.30. Revenue for the quarter came in at $274.4 million versus the consensus estimate of $268.06 million.

GUIDANCE:

USANA Health Sciences sees FY2021 EPS of $5.80-$6.00, versus the consensus of $5.93. USANA Health Sciences sees FY2021 revenue of $1.18-1.2 billion, versus the consensus of $1.19 billion.

For earnings history and earnings-related data on USANA Health Sciences (USNA) click here.